Emerson Electric vs Texas Instruments
EMR and TXN side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EMR and TXN compare
Texas Instruments is the larger company, worth 3.0 times as much as Emerson Electric ($275B against $92.0B).
On earnings, Emerson Electric is cheaper: it trades at 36.1× trailing earnings, against 45.8× for Texas Instruments.
Texas Instruments grew revenue faster over the last twelve months (16.7% versus 4.8% for Emerson Electric).
Texas Instruments keeps more of each dollar of sales as profit, with a net margin of 31.1% compared with 13.8% at Emerson Electric.
Both pay dividends: Emerson Electric yields 1.3% and Texas Instruments 2.4%.
Texas Instruments scores higher on the StockData Score (13 against 11 for Emerson Electric), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EMR | TXN |
|---|---|---|
| Size and price | ||
| Market cap | $92.0B | $275B |
| Share price | $164.94 | $300.84 |
| Change, 1 year | 20.9% | 87.7% |
| Change, 5 years | 68.4% | 55.6% |
| Beta (5Y) | 1.10 | 1.12 |
| Employees | 71K | 33K |
| StockData Score | ||
| Total score | 11 | 13 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 3 | 4 (better) |
| Health score | 3 | 3 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 36.1× (better) | 45.8× |
| P/S | 4.9× (better) | 14.1× |
| P/B | 4.5× (better) | 15.3× |
| EV/EBITDA | 21.6× (better) | 38.8× |
| P/FCF | 26.6× (better) | 51.3× |
| FCF yield | 3.8% (better) | 1.9% |
| Fair value | $142.44 | $190.34 |
| Margin of safety | −15.8% (better) | −58.1% |
| Growth | ||
| Revenue growth (TTM) | 4.8% | 16.7% (better) |
| Revenue growth, 5Y average | 1.4% | 4.1% (better) |
| Net income growth (TTM) | −2.8% | 20.1% (better) |
| EPS growth (TTM) | −1.7% | 20.3% (better) |
| EPS growth, 5Y average | 4.5% (better) | −1.8% |
| Profitability | ||
| Gross margin | 53.2% | 58.3% (better) |
| Operating margin | – | 37.3% |
| Net margin | 13.8% | 31.1% (better) |
| FCF margin | 18.6% | 27.5% (better) |
| Return on equity | 12.8% | 35.2% (better) |
| Return on invested capital | – | 25.3% |
| Financial health | ||
| Debt / equity | 0.64 (better) | 0.78 |
| Net debt / EBITDA | 2.29 | 0.97 (better) |
| Current ratio | 0.90 | 4.86 (better) |
| Altman Z-score | 4.32 | 12.92 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 1.3% | 2.4% (better) |
| Payout ratio | 47.8% | 84.5% |
| Years of dividend growth | 16 | 16 |
| Dividend growth, 5Y average | 1.1% | 8.1% (better) |
| Buyback yield | 1.00% (better) | 0.26% |
| Shareholder yield | 2.3% | 2.7% (better) |
| Ownership | ||
| Held by institutions | 82.5% | 89.5% |
| Held by insiders | 0.30% | 0.16% |
| Insider net buying, 12 months | −$7.9M (better) | −$119M |
| Superinvestors holding | 1 | 8 (better) |
| Short interest, % of float | 1.6% | 2.2% |
Go deeper
- EMR stock overview
- EMR income statement
- EMR valuation and score
- TXN stock overview
- TXN income statement
- TXN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.